Abstract
Purpose
People with schizophrenia have increased natural mortality. There is much speculation but little evidence about the reasons behind this. This paper describes a study designed to measure the impact of pre-selected clinical, demographic and lifestyle variables on the natural mortality of a cohort with schizophrenia.
Methods
Ten-year Cox proportional hazards regression analysis of a community cohort of 95 people with schizophrenia.
Results
Death from natural causes was significantly associated with psychosis (HR 2.62, 95% CI 1.13–6.07), age (HR 1.08, 95% CI 1.02–1.13) and cigarette smoking (HR 2.53, 95% CI 1.01–6.34) at outset. There was a trend to association with low dietary unsaturated fat (P = 0.06).
Conclusions
Active psychosis appears to predict natural mortality in people with schizophrenia. Mental health services should prioritise the effective treatment of psychosis. Further research is needed to clarify other risk factors and evaluate health promotion interventions.
Similar content being viewed by others
References
Rantanen H, Koivisto A-M, Salokangas R, Helminen M, Oja H, Pirkola S, Wahlbeck K, Joukamaa M (2009) Five-year mortality of Finnish schizophrenia patients in the era of deinstitutionalisation. Soc Psychiatry Psychiatr Epidemiol 44:135–142
Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time? Arch Gen Psychiatry 64:1123–1131
Kendler K (1986) A twin study of mortality in schizophrenia and neurosis. Arch Gen Psychiatry 43:643–649
Brown S, Kim M, Mitchell C, Inskip H (2010) Twenty five year mortality of a community cohort with schizophrenia. Br J Psychiatry 196:116–121
World Health Organisation (2009) Global health risks. Mortality and burden of disease attributable to selected major risks. WHO, Geneva
McEvoy J, Meyer J, Goff D, Nasrallah H, Davis S, Sullivan L, Meltzer H, Hsiao J, Stroup T, Lieberman J (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19–32
Brown S, Birtwistle J, Roe L, Thomson C (1999) The unhealthy lifestyle of people with schizophrenia. Psychol Med 29:697–701
McCreadie R (2003) Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 183:534–539
Okumura Y, Ito H, Kobayashi M, Mayahara K, Matsumoto Y, Hirakawa J (2010) Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort study. Schizophr Res 119:145–152
Saarni S, Saarni S, Fogelholm M, Heliovaara M, Perälä J, Suvisaari J, Lönnqvist J (2009) Body composition in psychotic disorders: a general population survey. Psychol Med 39:801–811
Druss B, Bradford W, Rosenheck R, Radford M, Krumholz H (2001) Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 58:565–572
Tihonen J, Lönnquist J, Wahlbeck K, Laukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374:620–627
Henderson C, Thornicroft G, Glover G (1998) Inequalities in mental health. Br J Psychiatry 173:105–109
Kilbourne A, Morden N, Austin K, Ilgen M, McCarthy J, Dalack G, Blow F (2009) Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry 31:555–563
Gibbons J, Horn S, Powell J, Gibbons J (1984) Schizophrenia patients and their families. A survey in a psychiatric service based on a DGH unit. Br J Psychiatry 144:70–77
World Health Organisation (1992) Schedules for clinical assessment in neuropsychiatry. WHO, Geneva
Roe L, Strong C, Whiteside C, Neil A, Mant D (1994) Dietary intervention in primary care: validity of the DINE method for diet assessment. Fam Pract 11:375–381
The Information Centre (2008) Health survey for England 2006. Cardiovascular disease and risk factors in adults. The Information Centre
Godin G, Shephard R (1985) A simple method to assess exercise behaviour in the community. Can J Appl Sport Sci 10:141–146
Bennett N, Dodd T, Flatley J, Freeth S, Bolling K (1995) Health survey for England 1993. HMSO, London
Walters S (2009) What is a Cox model? http://www.whatisseries.co.uk
Working Group of the Royal College of Physicians, Psychiatrists and General Practitioners (1995) Alcohol and the heart in perspective. Sensible limits reaffirmed. J R Coll Phys Lond 29:266–271
SPSS (2009) SPSS for windows, version 17.0. Lead Technologies, Inc, Chicago
Marder S, Essock S, Miller A, Buchanan R, Casey D et al (2004) Physical health monitoring in patients with schizophrenia. Am J Psychiatry 161:1334–1349
NICE (2009) Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Nice clinical guideline 82. National Institute for Health and Clinical Excellence, London
Brunner E, Stallone D, Juneja M, Bingham S, Marmot M (2001) Dietary assessment in Whitehall II: comparison of 7 d diet diary and food-frequency questionnaire and validity against biomarkers. Br J Nutr 86:405–414
Fletcher G, Balady G, Blair S, Blumenthal J, Casperson C et al (1996) Statement on exercise: benefits and recommendations for physical activity programs for all Americans. Circulation 94:857–862
Copeland L, Zeber J, Wang C-P, Parchamn M, Lawrence V, Valenstein M, Miller A (2009) Patterns of primary care and mortality among patients with schizophrenia or diabetes: a cluster analysis approach to the retrospective study of healthcare utilisation. BMC Health Serv Res 9:127
Tenorio-Martinez R, Lara-Munoz M, Medina-Mora E (2009) Measurement of problems in activities and participation in patients with anxiety, depression and schizophrenia using the ICF checklist. Soc Psychiatry Psychiatr Epidemiol 44:377–384
Gray R, Leese M, Bindman T, Becker L, Burti A, David K, Gournay K, Kikkert M, Koeter M, Puschner B (2006) Adherence therapy for people with schizophrenia: European multicentre randomised controlled trial. Br J Psychiatry 189:508–514
Gray R, Wykes T, Edmonds M, Leese M, Gournay K (2004) Effect of a medication management training package for nurses on clinical outcomes for patients with schizophrenia: cluster randomised controlled trial. Br J Psychiatry 185:57–162
Velligan D, Diamond P, Mintz J, Maples N, Li X, Zeber J, Ereshefsky L, Lam Y-W, Castillo D, Miller A (2008) The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull 34:483–493
Roberts L, Geppert C (2004) Ethical use of long-acting medications in the treatment of severe and persistent mental illness. Compr Psychiatry 45:161–167
Campion J, Checinski K, Nurse J (2008) Review of smoking cessation treatments for people with mental illness. Adv Psychiatr Treat 14:208–216
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brown, S., Mitchell, C. Predictors of death from natural causes in schizophrenia: 10-year follow-up of a community cohort. Soc Psychiatry Psychiatr Epidemiol 47, 843–847 (2012). https://doi.org/10.1007/s00127-011-0392-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00127-011-0392-6